Say goodbye to clunky AI tools—this simple, automated method for background extraction is faster and more reliable than you ...

The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...

Low-quality image placeholders (LQIPs) have a solid place in web page design. There are many different solutions but the main ...

There's no shortage of cancer immunotherapies trying ... Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months ...

Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

Dupixent US Net Sales: $2.6 billion, up 19% year-over-year. Libtayo Global Net Sales: $285 million, up 8% year-over-year on a constant currency basis. Free Cash Flow: $816 million for Q1 2025.

"It was low pay, no insurance, and no sense of community ... He said Anderson lacked the traditional background of Big Tech hires and recommended he pivot to another education role, which ...

Although I do believe the oncology portfolio still needs a few years to mature, this segment is approaching an inflection point, as Libtayo continues ... I have no business relationship with ...

The studio behind No Mercy, a recently released 3D visual novel featuring non-consensual sex and incest, has announced that it plans to remove the game entirely from Steam after the game attracted ...

Oncology Programs The Company submitted an sBLA to the FDA and a regulatory application in the EU for Libtayo (cemiplimab ... GAAP amounts are equivalent as no non-GAAP adjustments have been ...

Revenues also missed the Zacks Consensus Estimate of $3.27 billion. Sales of oncology drug, Libtayo, also missed estimates. Shares are trading down in response to lower-than-expected results.